Glaucoma Surgery: Trabeculectomy, Shunts, and MIGS

Glaucoma remains the leading cause of irreversible blindness worldwide, affecting an estimated 80 million people globally, with that number projected to reach 111.8 million by 2040 (World Health Organization). When eye drops and laser therapy fail to adequately lower intraocular pressure (IOP), surgical intervention becomes the next line of defense — and the landscape of surgical options has shifted dramatically over the past two decades. Three broad categories dominate the conversation: trabeculectomy, aqueous shunt devices, and the newer family of procedures grouped under minimally invasive glaucoma surgery (MIGS).

Trabeculectomy: The Long-Standing Standard

Trabeculectomy has been the gold-standard incisional glaucoma surgery since the 1960s. The procedure creates a small flap in the sclera (the white outer wall of the eye), allowing aqueous humor to drain from the anterior chamber into a subconjunctival space called a filtering bleb. The resulting bleb acts as a reservoir, and the fluid is gradually absorbed by surrounding tissues.

The pressure-lowering effect is substantial. The Tube Versus Trabeculectomy (TVT) Study, a landmark multicenter randomized clinical trial, reported that trabeculectomy reduced mean IOP from approximately 25.6 mmHg to 12.6 mmHg at one year — a reduction of roughly 50% (NEI/NIH). Surgeons often apply antifibrotic agents such as mitomycin C or 5-fluorouracil during the procedure to prevent scarring and bleb failure.

The trade-off is a meaningful complication profile. Hypotony (excessively low IOP), bleb leaks, infection (blebitis or endophthalmitis), and cataract progression all appear in the postoperative literature. The TVT Study found a 29% rate of reoperation or serious complications over five years for the trabeculectomy group (American Journal of Ophthalmology, Gedde et al., 2012). Careful patient selection, meticulous surgical technique, and diligent postoperative follow-up — often requiring multiple visits in the first month — remain essential.

Aqueous Shunts (Tube Implants)

Aqueous shunt devices, also called glaucoma drainage devices or tube implants, offer an alternative pathway for fluid to exit the eye. A small silicone tube is inserted into the anterior chamber (or sometimes the vitreous cavity), and it channels aqueous humor to an external plate sutured to the sclera, usually in the equatorial region of the globe. Common devices include the Ahmed Glaucoma Valve, the Baerveldt Glaucoma Implant, and the Molteno implant.

The Ahmed Baerveldt Comparison (ABC) Study demonstrated that the Baerveldt 350 implant achieved a lower mean IOP at five years (13.2 mmHg) compared to the Ahmed FP7 valve (15.8 mmHg), though the Baerveldt carried a higher early complication rate (Christakis et al., Ophthalmology, 2016). Shunts tend to be favored in eyes with prior failed trabeculectomy, active neovascular glaucoma, or significant conjunctival scarring — situations where bleb-dependent surgery is less likely to succeed.

One practical advantage: shunt surgery generally requires less intensive postoperative management than trabeculectomy, with fewer suture-lysis procedures and bleb-needling interventions. That said, tube erosion, diplopia from plate positioning, and corneal endothelial cell loss are recognized long-term concerns.

Minimally Invasive Glaucoma Surgery (MIGS)

MIGS represents a philosophical shift — trading the aggressive IOP reduction of traditional surgery for a gentler procedure with a substantially safer risk profile. These operations target the eye's natural drainage pathways (Schlemm's canal, the trabecular meshwork, the suprachoroidal space, or the subconjunctival space) through micro-incisions, often performed in conjunction with cataract surgery.

The iStent (Glaukos Corporation), approved by the FDA in 2012, was the first MIGS device to reach the U.S. market (FDA). It is a tiny titanium stent — just 1 mm in length — inserted into Schlemm's canal to bypass the trabecular meshwork. Subsequent devices have expanded the category: the iStent inject W, Hydrus Microstent (Alcon), Kahook Dual Blade (goniotomy), the Xen Gel Stent (a subconjunctival approach), and the iTrack/OMNI system for canaloplasty.

IOP reductions from MIGS devices are generally more modest — on the order of 3–8 mmHg — compared to trabeculectomy or shunts. A pivotal trial for the Hydrus Microstent showed that 77.3% of patients achieved an IOP reduction of 20% or more at 24 months when combined with cataract surgery, compared to 57.8% with cataract surgery alone (Samuelson et al., Ophthalmology, 2019). The appeal is the safety margin: MIGS devices carry low rates of hypotony, endophthalmitis, and vision-threatening complications.

MIGS is best suited for mild to moderate open-angle glaucoma. Patients with advanced disease or very high target pressures typically still require trabeculectomy or a shunt to achieve adequate IOP control.

How Surgeons Choose

The decision tree is not a simple flowchart. Factors include glaucoma severity, target IOP, the state of the conjunctiva, lens status (phakic versus pseudophakic), prior surgical history, and patient tolerance for postoperative visits. The American Academy of Ophthalmology's Preferred Practice Pattern notes that no single procedure is universally superior; the choice involves a risk-benefit discussion tailored to each patient's disease stage and life circumstances (AAO).

A common clinical sequence: MIGS at the mild-to-moderate stage (often combined with cataract extraction), followed by trabeculectomy or a shunt if disease progresses. Some surgeons bypass MIGS entirely in advanced cases, proceeding directly to traditional filtering surgery.

Frequently Asked Questions

What is the typical recovery time after trabeculectomy?

Most patients experience significant visual recovery within 2–4 weeks, though IOP stabilization and bleb maturation can take 2–3 months. Frequent postoperative visits — sometimes weekly for the first month — are standard to manage healing and adjust sutures.

Are MIGS procedures covered by insurance?

Most MIGS devices carry FDA approval and are covered by Medicare and commercial insurance when performed with cataract surgery. Standalone MIGS without concurrent cataract extraction has more variable coverage depending on the specific device and payer.

Can glaucoma surgery restore lost vision?

Glaucoma surgery lowers intraocular pressure to slow or halt further optic nerve damage. It does not reverse vision already lost to glaucomatous optic neuropathy. The goal is preservation, not restoration — an important distinction during preoperative counseling.

How long do aqueous shunts last?

Aqueous shunt devices can function for decades. The TVT Study reported sustained IOP control at five years, and long-term data beyond ten years exist for the Molteno and Baerveldt implants, though some patients require supplemental medication or revision surgery over time.

References

• World Health Organization — Blindness and Visual Impairment Fact Sheet
• National Eye Institute — Glaucoma
• Gedde et al., TVT Study Five-Year Results, American Journal of Ophthalmology, 2012
• Christakis et al., ABC Study Five-Year Results, Ophthalmology, 2016
• FDA — iStent inject Trabecular Micro-Bypass System
• Samuelson et al., Hydrus Microstent Pivotal Trial, Ophthalmology, 2019
• American Academy of Ophthalmology — Primary Open-Angle Glaucoma Preferred Practice Pattern

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)